Company intelligence / Profile preview
Shenzhen SiBiono GeneTech
Shenzhen, Guangdong, Chinasibiono.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Shenzhen SiBiono GeneTech is a pioneer in commercial gene therapy. Its flagship product Gendicine®—a recombinant human p53 adenovirus injection—became the world’s first approved and marketed gene therapy drug in 2003/2004 for head and neck cancers in China. The company continues to develop additional gene therapies targeting various cancers with several programs at preclinical or clinical stages[1][2][3][6].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Gene therapyOncolytic virus
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Collaborations with domestic & overseas research organizations/universities during Gendicine development period; distribution partnerships within China (~15 companies distribute Gendicine)
Beyond the preview
Go deeper on Shenzhen SiBiono GeneTech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shenzhen SiBiono GeneTech.